Skip to content No products added!
(Solution) Developing Imatinib that Transformed Leukemia Treatment
Original price was: $40.00.$10.00Current price is: $10.00.
Description
Factors Involved in Developing Imatinib that Transformed both Leukemia Treatment and Cancer Research
Prompt
“Critically analyse how factors such as scientific discovery,
economics, policy and medical and legal practice interacted to
influence the innovation of a pharmaceutical product.”
Pharmaceutical product can be a medical product and should be single product. The pharmaceutical product should also have an adequate information about scientific discover, economics, policy and medical practice to innovation.
Table of Contents
Introduction. 3
Factors that Interacted in Developing Imatinib. 3
Scientific Discovery. 4
Economics. 5
Policy Practice. 5
Medical Practice. 6
Legal Practice. 7
Conclusion. 8
References. 9
Solution
Introduction
Innovation involves creating and applying new ideas or products to drive profitable change and capitalize on emerging opportunities. As Yu et al. (2025) explain, innovation is a contextual concept shaped by various influencing factors and requires proactive practices to structure, organize, and encourage it. In the pharmaceutical industry, innovation unfolds within a complex environment characterized by high research and development costs, stringent government regulation, lengthy product development timelines, and a low success rate of marketable drugs compared to the number of initial chemical compounds (Kim & Phillips, 2013). Consequently, no single factor solely accounted for the development of Imatinib, a drug that revolutionized leukemia treatment and cancer research.
Instead, the development of Imatinib, discovered in the late 1990s by biochemist Nicholas Lyndon at Novartis (formerly Ciba-Geigy) for the treatment of chronic myeloid leukemia (CML), resulted from the interplay of multiple factors (Iqbal & Iqbal, 2014). This paper explores the interplay of scientific, economic, legal, and clinical factors that enabled the development of Imatinib, an innovation that revolutionized leukemia treatment and reshaped cancer research.
Factors that Interacted in Developing Imatinib
Imatinib marked a departure from conventional chemotherapy drugs, as it became the first genetically targeted therapy (Hunter, 2007). Its development resulted from the interaction of multiple factors, including scientific discovery, economic considerations, policy implementation, medical practice, and legal frameworks. Examining how these factors intersected provides critical insight into the processes that enabled the creation of this groundbreaking drug.
| Factor | Key Contributions | Impact on Imatinib |
| Scientific Discovery | – Identification of BCR-ABL fusion gene – Development of tyrosine kinase inhibitors – Collaboration between researchers and pharmaceutical scientists | Enabled targeted drug design and validation of Imatinib as a selective treatment for CML |
| Economic Factors | – High R&D costs in pharma- Revenue expectations to offset failures – Pricing and market demand dynamics | Justified Novartis’s investment and influenced pricing strategy, despite later affordability concerns |
| Policy and Regulation | – Public funding for basic research – FDA’s stringent approval requirements – Patent protection mechanisms | Provided infrastructure for innovation while ensuring drug safety and efficacy through regulatory oversight |
| Medical Practice | – Early clinical adoption – Role of influential physicians and research hospitals – Hospital formularies and prescribing behavior | Accelerated clinical acceptance of Imatinib, especially as an orally administered, effective cancer therapy |
| Legal Environment | – Patent filings and disputes – Global intellectual property laws – Regulatory compliance burdens | Shaped global availability, pricing, and legal protections; delayed or limited access in some jurisdictions |
Please click the icon to access the paper in full.
Reviews
There are no reviews yet.